A novel series of benzoic acid derivatives as VLA-4 antagonists were synthesized. Optimization, focusing on activity and lipophilicity needed for cell permeability, resulted in the identification of 15b and 15e with good activity (IC 50 ‫6.1؍‬ nM each) and moderate lipophilicity (Log D‫,0.2؍‬ 1.8) . Furthermore, 15e demonstrated efficacy in murine asthma model by an oral dose of 30 mg/kg.
VLA-4 (very late antigen 4, a 4 b 1 integrin, CD49d/CD29) is a key cell receptor expressed on most leukocytes. 1) Natural ligands include VCAM-1 (vascular cell adhesion molecule-1) expressed on cytokine-stimulated endothelial cells, the alternatively spliced connecting segment-1 domain of fibronectin on the extracellular matrix, [2] [3] [4] and junctional adhesion molecule 2 on endothelial cells. 5) Through interaction with ligands, VLA-4 plays an important role in the process of adhesion, migration, and activation of inflammatory leukocytes at sites of inflammation. Anti-VLA-4 antibodies or small molecular VLA-4 antagonists [6] [7] [8] [9] [10] [11] [12] have been reported to inhibit leukocyte infiltration into extravascular tissue and prevent tissue damage in models of inflammatory such as asthma, 13) multiple sclerosis, 14, 15) rheumatoid arthritis, 16) and inflammatory bowel disease. 17, 18) It has recently been reported that the humanized monoclonal anti-a 4 antibody, Tysabri (Elan Pharmaceuticals Inc. and Biogen Idec Inc.), [19] [20] [21] demonstrated promising results in treating patients with multiple sclerosis, Crohn's disease, and rheumatoid arthritis in clinical trials. Therefore, the development of small molecular VLA-4 antagonists with acceptable oral pharmacokinetic profiles are viewed as a reasonable approach to a novel class of therapeutic agents.
We have recently reported the identification of a morpholinyl-piperidinylacetic acid 1 as a potent VLA-4 antagonist (IC 50 ϭ4.4 nM), which showed efficacy in a murine airway inflammation model by oral administration (Fig. 1) . 22) Unfortunately, 1 had a poor pharmacokinetic profiles such as low oral availability and high plasma clearance (FϽ1%, 69 ml/min/kg) in rats. 22) To improve the poor pharmacokinetic property, structural modifications were made to this class of compounds. As a result of this study, 3-hydroxyprolyl-1-piperazinylacetic acid 2 (IC 50 ϭ1.1 nM) and 3,4-dihydroxyprolyl-1-piperazinylacetic acid 3 (IC 50 ϭ1.4 nM) were identified; both these compounds have moderate plasma clearance (2, 30 ml/min/kg; 3, 21 ml/min/kg) in rats. 23) We also have made it clear that the improvement of plasma clearance is caused by the change of the main excretion pathway, from bile for 1 to urine for 2 and 3. 12) Unfortunately, neither 2 nor 3 showed any oral availability. From result of permeability assay using Madin-Darby canine kidney (MDCK) cell monolayers, it was found that 1, 2, and 3 showed low permeability (P app values, 1: 0.02ϫ10 Ϫ6 cm/s; 2: Ͻ0.15ϫ10 Ϫ6 cm/s, 3: Ͻ0.05ϫ10 Ϫ6 cm/s). These results stand contrast to value for metoprolol (17.3-20 .3ϫ10 Ϫ6 cm/s), which exhibits good oral availability in human. In addition, it was found that these compounds showed low Log D values (1, Ϫ0.7; 2, 3, Ϫ3), suggesting that their poor permeability is probably caused by their low lipophilicity. Further attempts to modify 2 and 3 to ethyl-ester, as a pro-drugs, were conducted as one way to increase the absorption across the intestinal epithelium. However, the strategy did not lead to a significant improvement of oral availability in rats (FϽ3%). Since the extremely low lipophilicity of 2 and 3 is probably responsible at least in part for the improvement in their plasma clearance, but, this physicochemical characteristic is at odds with good cell permeability. Thus, further development on these compounds were halted.
During the course of the study, we had also identified prolyl-benzoic acid derivative 6 (IC 50 ϭ1.6 nM, Fig. 1 ). This compound shows relatively higher lipophilicity (Log Dϭ 0.68) than those of 2 and 3. Additionally, with regard to plasma clearance, given that compounds with relatively high lipophilicity tend to bind to serum albumin, 24) this characteristic would improve the maintenance at a given blood concentration. Consequently, we thought that benzoic acid derivatives might be useful to achieve a desired compound with low plasma clearance and good oral bioavailability. Thus, compound 6 was chosen for further studies. In addition to the VLA-4/VCAM-1 binding assay used previous studies, we performed to evaluate the activities of compounds in the presence of 3% human serum albumin (HSA) to estimate their effectiveness in vivo.
4-(Pyrrolidinyl)methoxybenzoic Acid Derivatives as a Potent
The modification of the amide bond between the pyrrolidine ring and the benzoic acid is performed firstly, since it has been found that the removal of oxygen atom in the corresponding amide bond of prolyl-1-piperazinylacetic acid derivative 4 (IC 50 ϭ1.6 nM, Fig. 1 ) dose not affect on the activity (5, IC 50 ϭ1.6 nM, Fig. 1 ). 23) Next, appending a variety of substituents into pyrrolidine ring and benzene ring of benzoic acid portion of 6 was focused on.
In this paper, we wish to report the optimization efforts on the physicochemical properties of the benzoic acid derivatives that retain the activity. We also present the results of representative compounds in treating a murine model of asthma and the pharmacokinetic profiles.
Chemistry
The syntheses of benzoic acid derivatives 9a-g (Synthetic route A), 12a-p (Synthetic route B), and 15a-k (Synthetic route C) are shown in Chart 1. Pyrrolidine derivatives 8a-c, 8e, 11a-n, and 14a-g were condensed with 3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetic acid (7a) or penetafluorophenyl 3-methoxy-4-[N-(2-methylphenyl)-ureido]phenylacetate (7b) using EDC and HOBt followed by basic hydrolysis to produce 9a-c, 9e, 12a-n, and 15a-g. After the hydrolysis, the hydrogenation of CϭC double bond in 9b afforded 9d. Oxidation of sulfide 10, which was obtained in the preparation on 9e, by using mCPBA (1 eq or 2.2 eq) and basic hydrolysis resulted in 9f and 9g, respectively. In the case of 12o and 12p, each of bearing hydroxyl group in the pyrrolidine ring, deprotection of the O-protective groups was conducted before basic hydrolysis of intermediates 13m and 13n. Compound 15h was prepared from 15g by SnCl 2 reduction of the NO 2 group. The subsequent standard N-acylation and N-alkylation protocols provided 15i and 15j, respectively. Compound 15k, with a N-methyl group at the 3-position of benzoic acid, was synthesized from intermediate 16, which was obtained in the preparation on 15g, via mono-N-methylation followed by basic hydrolysis.
Pyrrolidine derivatives 8a-c, 8e, 11a-n, and 14a-g were prepared from L-proline derivatives 17, 22, and 26 23, 25) as shown in Chart 2-6.
Compound 8a, with a methylamino linker (CH 2 NH) between the pyrrolidine ring and the benzoic acid moiety, was prepared from N-Boc-L-prolinal (17) with methyl 4-aminobenzoate by use of NaBH 3 CN, followed by deprotection of the Boc group with TFA as shown in Chart 2.
Compound 8b with an ethenyl linker (CHϭCH) and 8c with an ethynyl linker (CϵC) were prepared as shown in Chart 3. N-Boc-L-prolinal (17) was subjected to Wittig-Honner reaction with ethyl 4-(diethoxyphosphorylmethyl)benzoate, 26) followed by deprotection of the Boc group to give 8b. On the other hand, 17 was converted to 2-ethynylpyrrolidine 20 according to the Trybulsk's protocol. 27) Following Pd catalyzed coupling of 20 with ethyl 4-iodobenzoate, deprotection of Boc group afforded 8c.
The synthesis of 8e containing a methylthio linker (CH 2 S) was achieved in 4 steps as shown in Chart 4. Following tosylation 28) of N-Boc-L-prolinol (22) , coupling of 23 with 4-iodothiophenol 29) in the presence of NaH yielded 24. Subsequently, 24 was subjected to Pd catalyzed methoxycarbonylation reaction with CO and MeOH, followed by deprotection of the Boc group to afford 8e.
Substituted pyrrolidines 11a-n, which contain a methyloxy linker (CH 2 O) at 2-position in the pyrrolidine ring, were prepared as shown in Chart 5. Substituted proline derivatives 26a, b, 26d, 26f-j, and 26m, n, which were commercially available or easily prepared from N-Boc-(4R)-hydroxy-L-proline, 23, 25) were reduced with borane-dimethylsulfide complex, followed by coupling with methyl 4-hydroxybenzoate employing Mitsunobu reaction to afford 27a, b, 27d, 27f-j, and 27m, n. Additionally, 27c, 27e, 27k, and 27l were readily prepared from 27b. Thus, the selective hydrolysis of the acetoxy group in 27b with K 2 CO 3 /MeOH and Mitsunobu reaction of the resulting (4R)-hydroxypyrrolidine derivative with acetic acid provided 27c with inversion of configuration at C-4. The acetoxy group in 27c was also selectively hydrolyzed under the same condition to give the (4S)-hydroxypyrrolidine derivative, which was subjected to O-methylation using MeI and NaH to afford 27e. The (4S)-hydroxypyrrolidine derivative was also converted to 27k via triflation followed by SN2 displacement with dimethylamine (Me 2 NH). In an analogous manner, 27b was readily converted to 27l. The N-protective groups of 27a-n were removed according to standard deprotection protocols to furnish 11a-n.
Compounds 14a-g, which have substituents on the benzene ring of the benzoic acid portion, were synthesized as shown in Chart 6. Compound 22 was coupled with 4-bromo-3-methylphenol, 4-iodo-2-methylphenol, and 3,5-dimethyl-4-iodophenol by means of Mitsunobu reaction to give 28a-c, respectively. The methoxycarbonylation was carried out by treatment of 28a-c with n-BuLi and methyl chloroformate or Pd(OAc) 2 in MeOH under CO atmosphere to afford 29a-c, which were followed by deprotection of the Boc group to afford 14a-c, respectively. Additionally, N-Boc-L-prolinol (22) was also converted to 14d-g using commercially available 3-or 3,5-substituted benzoic acid derivatives in a manner similar to that described for preparation of 11 in Chart 5.
Results and Discussion
The compounds were evaluated for their VLA-4 inhibitory activities in the receptor binding assay, with or without the addition of 3% human serum albumin (HSA). Additionally, distribution coefficient [Log D, n-Octanol/PBS (pH 7.4)] was determined to assess the oral bioavailability. The results are summarized in Tables 1-3.  Table 1 shows the results in the modifications of the linker portion (CONH as in 6) between the pyrrolidine ring and the benzoic acid portion. Almost all the linkers maintained the good activity with IC 50 values of less than 10 nM. However, the CH 2 S linker (9e) and the CH 2 SO 2 linker (9g) slightly de-creased the activity. These modifications suggest that the amide bond in the liker portion was not necessary to maintain an activity, which SAR was similar to that of piperazine analogue described above. As for the activity in the presence of HSA, the order was nearly the same with that of the activity in the absence of HSA. In addition, considering that the ratio of IC 50 (ϪHSA) to IC 50 (ϩHSA), it was found that CH 2 O linker (12a) would less likely to be affected negative by HSA. With regard to the lipophilicity, all compounds measured, except for 9f with the CH 2 SO linker (Log Dϭ Ϫ0.4), showed Log D values of more than 1.0, indicating that modification of CONH linker (6, Log Dϭ0.68) would increase of the lipophilicity without lack of the activity. On the other hand, 9a with Log D value of 1.6 showed the ratio value of 2.8, whereas 9f with Log D value of Ϫ0.4 showed the ratio value of 6.3, indicating that the apparent correlation between the ratio and the Log D value was not recognized. We consider that potent compound with IC 50 value about 1 nM might not be affected in the binding activity in the presence of HSA. From these results, and the relative ease of synthesis, we considered that compounds contained CH 2 O linker would be favorable for the further optimization. Thus, next we turned our attention to appending substituents on the pyrrolidine ring and the benzene ring of benzoic acid portion beginning with compound 12a.
The result of introduction substitutions onto 3, 4, or both positions on the pyrrolidine ring is shown in Table 2 . As for the configuration at the 4 position on the pyrrolidine ring, it was found that the S isomers (12c, WϭOH; 12e, WϭOMe; 12h, WϭF; 12l, WϭNMe 2 ) bound the receptor about 6 to 7 fold more potent than the corresponding R isomers (12b, WϭOH; 12d, WϭOMe; 12g, WϭF; 12k, WϭNMe 2 ). Despite the bulkiness (12f, Wϭ2-O-naphtyl) of the substituents at the 4 position, there was almost no effect on activity. As for piperazine and piperidine acetic acid derivatives, 11) the configuration, bulkiness, and the nature of substituents at the same position on the pyrrolidine ring did not affect the activity. The fact suggests that the SAR of the benzoic acid derivatives would be subtly different from those of both piperazine and piperidine acetic acid derivatives. The substituents [12p, Wϭ(3R)-OH; 12n, Wϭ(3R)-OBn] at the 3-position on the pyrrolidine ring also maintained activity. Although 12o [Wϭ(3R,4S)-dihydroxypyrrolidine] showed good activity, the shielding of the hydroxyl groups of 12m by isopropylidene ketal was 30-fold loss of activity compared with 12o. The results of introduction of several substitutes into the benzoic acid portion in 12a are shown in Table 3 . The substituents, including methyl (15b), methoxy (15d), chloro (15e), nitro (15g), amino (15h), methylamino (15k), dimethylamino (15i), and acetylamino (15j), were tolerated at 3 position on the benzene ring. However, 2-methyl (15a) and 3,5-dichloro (15f) substituents decreased binding affinity, with IC 50 values of 6.0 nM for 15a and 47 nM for 15f. Unexpectedly, the introduction of 2,5-dimethyl substituents (15c) caused a loss of activity at 1 mM. Among these compounds, 15b and 15e showed higher Log D values (15b, 2.0; 15e, 1.8) than 12a, while the activities in the presence of HSA were relatively maintained.
On the basis of activity and Log D value, 15b and 15e were selected for in vivo testing of VLA-4 inhibitory activity. These compounds were evaluated for Ascaris-antigen sensitized murine airway inflammation model by an oral dose of 30 mg/kg/b.i.d. for 2 d (Fig. 2) . The result showed that 15e inhibited eosinophil infiltration into bronchial alveolar lavage (BAL) fluid by 72% compared with the vehicle alone. Compound 15b, however, only weakly inhibited (30%) eosinophil infiltration in mice (data not shown). Next, the pharmacokinetic of 15e in rats was evaluated to determine whether this compound attained any improvement over the initial lead compound 1. Compound 15e showed low bioavailability Fϭ5%, which indicated a slight improvement compared with 1 (FϽ1%) ( Table 4 ). In order to evaluate the causes of the difference in oral absorption, 15e was assessed for the cell permeability using Madin-Darby canine kidney (MDCK) cell monolayers. As a result, 15e demonstrated P aap values of 0.78ϫ10 Ϫ6 cm/s, indicating that 15e is about 40-fold more permeable than 1. In comparison, the P app value of metoprolol, which is known to show good oral availability in humans is 17.3-20.3ϫ10 Ϫ6 cm/s. These results suggest that compound needs to enhance its permeability. As for the plasma clearance following i.v. administration, there was no difference between 15e (Clϭ59 ml/min/kg) and 1 (Clϭ69 ml/min/kg), disappointingly.
Conclusion
A novel series of benzoic acid derivatives were explored to obtain VLA-4 antagonists with good pharmacokinetic profiles. We focused on increasing the lipophilicity of lead compounds to enhance the cell permeability while maintaining potent VLA-4 inhibitory activity. Thus, modification of the linker portion between the pyrrolidine ring and benzoic acid, and introduction of a variety of substituents into the pyrrolidine ring and benzene ring of benzoic acid as in 6 were conducted. These modifications yielded several compounds with potent activity even in the presence of HSA and moderate lipophilicity. Among them, compound 15e demonstrated efficacy in an in vivo model of asthma by an oral dose of 30 mg/kg. However, this compound did not show a significant improvement in oral pharmacokinetic profile compared with the initial lead 1. Further improvements and structural modifications of this series of compounds will be presented in forthcoming publications. 1520 Vol. 54, No. 11 
Experimental
Melting points were determined on a MP-J3 (YANACO) and were uncorrected. Column chromatography was performed with silica gel 60 (Merck, particle size 0.060-0.200 or 0.040-0.063). Flash column chromatography was performed using a Biotage Si (Biotage) or a Hi-Flash (YAMAZEN). Thin-layer chromatography (TLC) was performed on pre-coated TLC glass sheets with silica gel 60 F 254 (Merck).
1 H-NMR spectra were recorded on a JNM-EX-400 spectrometer (JEOL), and chemical shifts are given in ppm (d) from tetramethylsilane as the internal standard. IR spectra were recorded on a 270-30 spectrometer (HITACHI). ESI mass spectra were recorded on an API-150EX spectrometer (SCIEX). FAB mass spectra were recorded on a JMS-HX110 spectrometer (JEOL). HR-FAB mass spectra were recorded on a JMS-700 spectrometer (JEOL). 4-[1-[3-Methoxy-4-[N-(2-Methylphenyl) Hydroxy-1-[3-methoxy-4-[N-(2-methylphenyl) 
4-[(4S)-Hydroxy-1-[4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic Acid (12c)

4-[(4S)-Methoxy-1-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic Acid (12e)
4-[1-[3-Methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(4S)-(2-naphthyloxy)-(2S)-pyrrolidinyl]methoxybenzoic Acid (12f)
4-[4,4-Difluoro-1-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoate (12i)
4-[(4R)-Chloro-1-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic Acid (12j)
4-[(3R)-Benzyloxy-1-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic Acid (12n)
4-[1-[3-Methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)-
Methyl 4-[(3R)-Benzyloxy-1-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoate (13n) as an
4-[(3R)-
3-Amino-4-[1-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic Acid (15h) A suspension of 4-[1-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacethyl]-(2S)-pyrrolidinyl
methoxy]-3-nitrobenzoic acid (15g) (101 mg, 0.190 mmol) and 5 % Pd/C (247 mg) in MeOH (5 ml) was hydrogenated under 1 atom hydrogen atmosphere at room temperature for 21 h. After the catalyst was removed by filtration, the filtrate was concentrated to dryness. The residue was purified by column chromatography on silica gel with CHCl 3 
3-Acetylamino-4-[1-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic Acid (15i) A solution of 3-amino-4-[1-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-(2S)
pyrrolidinyl]methoxybenzoic acid (15h) (130 mg, 0.244 mmol) and DMAP (2.9 mg, 0.024 mmol) in pyridine/acetic anhydride (5/5 ml) was stirred at room temperature for 2 h. The mixture was poured into water and extracted with CHCl 3 . The combined extracts were dried over Na 2 SO 4 3-N,N-Dimethylamino-4-[1-[3-methoxy-4-[N-(2-methylphenyl) 
Methyl 4-[1-(tert-Butoxycarbonyl)-(2S)-pyrrolidinyl]methylaminobenzoate (18)
A mixture of methyl 4-aminobenzoate (1.52 g, 10.04 mmol) and N-Boc-L-prolinal (17) (3.00 g, 15.1 mmol) in toluene (30 ml) was refluxed with stirring for 3 h. The reaction mixture was cooled to room temperature and dried over Na 2 SO 4 . After removing the solvent under reduced pressure, the resulting precipitate was diluted with MeOH/HOAc (27/3 ml), then NaBH 3 CN (1.33 g, 20.1 mmol) was added and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was poured into water and extracted with EtOAc. The combined extracts were washed with water and brine, dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was purified by chromatography on silica gel with n-hexane/EtOAc (3/1, v/v) as an eluent to afford compound 18 (2.17 g, 65%) as a pale yellow oil. 1 
Ethyl 4-[2-[1-(tert-Butoxycarbonyl)-(2S)-pyrrolidinyl]-(E)-ethenyl]-benzoate (19)
To a solution of ethyl 4-(diethoxyphosphorylmethyl)benzoate 26) (904 mg, 3.01 mmol) in THF (20 ml) was added LiHMDS (1.0 M in THF, 3 ml, 3.00 mmol) at Ϫ78°C. After 1 h stirring, N-Boc-L-prolinal (17) (500 mg, 2.51 mmol) in THF (10 ml) was added to the reaction mixture, and allowed to warm up to room temperature over 1 h. After being stirred for 2 h, the mixture was poured into water and extracted with EtOAc. The combined extracts were washed with brine, dried over MgSO 4 , and evaporated. (20) 27) (1.95 g, 10 mmol) in i-Pr 2 NH (20 ml) over 10 min at room temperature under an atmosphere of nitrogen. After 3 h stirring, the mixture was poured into water and extracted with EtOAc. The combined extracts were washed with brine, dried over MgSO 4 , and evaporated. The residue was purified column chromatography on silica gel with nhexane/EtOAc (10/1, v/v) as an eluent to give compound 21 (2.77 g, 81%) as a colorless oil. (21) 28) (2.39 g, 6.75 mmol) in pyridine (12.7 ml) was added 8 N KOH (1.27 ml) at room temperature. After 4 h stirring, the reaction mixture was diluted with EtOAc. The solution was washed with H 2 O, sat. NH 4 Cl, brine, and dried over Na 2 SO 4 . The organic layer was concentrated under a reduced pressure. The residue was purified column chromatography on silica gel with n-hexane/EtOAc (5/1, v/v) as an eluent to afford compound 24 (1.49 g, 53%) as a pale yellow oil. 1.49 g, 3.56 mmol) , Et 3 N (1.09 ml, 7.84 mmol), Pd(OAc) 2 (40 mg, 0.178 mmol), and 1,3-bis(diphenylphosphino)propane (73.4 mg, 0.178 mmol) in DMSO/MeOH (16/13 ml) was induced CO gas for 5 min, and stirred at 70°C for 12 h. After cooling to room temperature, the mixture was concentrated to a small volume. The resulting residue was diluted with EtOAc, washed with brine, and then dried over Na 2 SO 4 . After the solvent was removed, the residue was purified column chromatography on silica gel with n-hexane/EtOAc (5/1, v/v) as an eluent to afford methyl 4-[1-(tert-butoxycarbonyl)-(2S)-pyrrolidinyl]methylthiobenzoate (25) (1.16 g, 93%) as a yellow oil.
To a stirred solution of methyl 4-[1-(tert-butoxycarbonyl)-(2S)-pyrrolidinyl]methylthiobenzoate (25) (1.16 g, 3.32 mmol) in CH 2 Cl 2 (20 ml) was added TFA (4 ml), and the mixture was stirred at room temperature for 1.5 h. The solvent was removed under a reduced pressure and the residue was treated with 1 M NaOH. The mixture was extracted with CHCl 3 . The extract was washed with brine, dried over KOH, and concentrated under reduced pressure to afford compound 8e (767 mg, 92%) as a yellow oil. 
Preparation of Methyl 4-[1-(tert-Butoxycarbonyl)-(2S)-pyrrolidinyl]-methoxybenzoate (11a) (General procedure C). N-Boc-L-prolinol (22)
To a stirred solution of N-Boc-L-proline (26a) (20.0 g, 92.9 mmol) in THF (500 ml) was added BH 3 · DMS (9.7 ml, 102 mmol) and the mixture was refluxed for 1 h with stirring. After cooling to room temperature, the mixture was concentrated. The resulting residue was diluted with water and extracted with CH 2 Cl 2 . The combined extracts were washed with sat. NaHCO 3 and brine, which was dried over Na 2 SO 4 and evaporated to afford compound 22 (15.6 g, 83%) as a colorless crystalline powder. N-Boc-L-prolinol (22) is commercially available. 9 mmol) and Ph 3 P (4.06 g, 15.5 mmol) in THF (40 ml) was added diisopropyl azodicarboxylate (3.10 ml, 15.7 mmol) and the reaction mixture was heated under reflux for 14 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel with n-hexane/EtOAc (6/1, v/v) as an eluent to afford compound (27a) (3.34 g, 77%) as a colorless oil. The following compound 11b, 11f-j, and 11n were prepared from 26b, 26f-j, and 26n, respectively, according to general procedure C.
Methyl 4-(N-tert-Butoxycarbonyl-4-hydroxy-(2S)-pyrrolidinylmethoxy)-benzoate (27b)
Colorless oil (yield, 39%); 12 (5H, m), 3.03-3.29 (1H, m), 3.73-3.80 (1H, m), 3.88 (3H, s) 
Methyl 4-[1-tert-Butoxycarbonyl-(4S)-(2-naphthyloxy)-(2S)-pyrro
1-(tert-Butoxycarbonyl)-(4R)-chloro-(2S)-pyrrolidinylcarboxylic Acid (26j)
To a stirred solution of methyl 1-(tert-butoxycarbonyl)-(4S )-hydroxy-(2S)-pyrrolidinylcarboxylate (1.81 g, 7.34 mmol) in CCl 4 /CH 2 Cl 2 (10/10 ml) was added Ph 3 P (3.87 mmol, 14.8 mmol) and the reaction mixture was stirred at room temperature for 2 h. To the mixture was added EtOH (5 ml) and the reaction mixture was stirred at room temperature overnight. After removal of the solvent, the residue was purified by column chromatography on silica gel with n-hexane/EtOAc (3/1, v/v) as an eluent to afford methyl 1-(tert-butoxycarbonyl)-(4R)-chloro-(2S)-pyrrolidinylcarboxylate (1.36 g, 70%) as a colorless oil. 12 mmol) in THF (10 ml) was added 0.5 M NaOH (10 ml) and heated under reflux for 1.5 h. After cooling to room temperature, the mixture was poured into 1 M HCl and the mixture was extracted with CHCl 3 /MeOH (9/1, v/v). The combined extracts were washed with brine, dried over Na 2 SO 4 and evaporated to afford compound (26j) (1.28 g, quant.) as colorless oil. 88 (3H, s), 4.30-4.41 (2H, m), 4.50-4.55 (1H, m), 6.90-6.92 (2H, m) 74 mmol) and Ph 3 P (2.44 g, 9.30 mmol) in THF (30 ml) was added diisopropyl azodicarboxylate (1.83 ml, 9.29 mmol) and the reaction mixture was heated under reflux for 5 h. After cooling to room temperature, the mixture was evaporated. The residue was filtered on silica gel with toluene/acetone (5/1, v/v) as an eluent to afford methyl 4-[1-tert-butoxycarbonyl-(4R)-methoxy-(2S)-pyrrolidinyl]methoxybenzoate (27d) including inseparable material.
To a solution of methyl 4-[1-tert-butoxycarbonyl-(4R)-methoxy-(2S )-pyrrolidinyl]methoxybenzoate (27d) in CH 2 Cl 2 (20 ml) was added TFA (20 ml) at room temperature. After 12 h stirring, the mixture was concentrated in vacuo. The residue was made basic by sat. NaHCO 3 and extracted with CHCl 3 . The combined extracts were washed with brine, dried over K 2 CO 3 , and evaporated. The residue was purified by column chromatography on silica gel with CHCl 3 /MeOH (30/1 to 30/2, v/v) as an eluent to afford compound 11d (1.67 g, 81% for 2 steps) as a reddish brown oil. 
Methyl 4-[1-tert-Butoxycarbonyl-(4R)-dimethylamino-(2S)-pyrrolidinyl]methoxybenzoate (27k)
To a stirred solution of methyl 4-[1-tert-butoxycarbonyl-(4S )-hydroxy-(2S )-pyrrolidinyl]methoxybenzoate (300 mg, 0.85 mmol) in CH 2 Cl 2 (10 ml) was added DIPEA (2.08 ml, 12.0 mmol) at room temperature and cooled to Ϫ78°C. After 30 min stirring, Tf 2 O (0.56 ml, 2.42 mmol) was added to the mixture at same temperature and the solution was stirred for 30 min. Two mol/l Me 3 NH in THF (2.13 ml, 4.26 mmol) was added to the reaction mixture at Ϫ78°C. After 20 min stirring at Ϫ78°C, the reaction mixture was raised to 5°C and stirred for 18 h. The reaction mixture was poured into sat. NaHCO 3 solution and extracted with CH 2 Cl 2 . The combined extracts were washed with brine. After drying over Na 2 SO 4 , the extracts were concentrated in vacuo. The residue was purified by flush column chromatography (Biotage 25S) with MeOH/EtOAc (0-40%, v/v) as an eluent, to afford compound 27k (380 mg, over yields) including inseparable materials as a red oily solid. 1 H (mm)] with lids in unidirectional air flow rooms maintained controlled temperature (23Ϯ2°C) and relative humidity (55Ϯ20%) on a 12 h light-dark cycle. Animals were provided food and tap water ad libitum. Norm-Based Group Building ver. 5.0.0 (Visions) was used to divide the animals into groups. Each group consisted of 7 animals. Mice received oral administration of cyclophosphamide (Endoxane, Shionogi & Co. Ltd.) dissolved in 5% (w/v) carboxymethylcellulose (CMC) at a dose of 150 mg/10 ml/kg (day 0). A solution containing 500 mg Ascaris suum extract (LSL Co., Ltd.) for every 0.2 ml saline wad prepared. The solution also contained 5 mg aluminum hydroxide as an adjuvant. On day 2, 0.2 ml of the antigen solution was injected intraperitoneally into each mouse. On day 14, the same antigen solution was injected intraperitoneally as a booster. Finally, on day 22, mice were anesthetized with intraperitoneal injection of 70 mg/10 ml/kg of pentobarbital sodium. After 10 min, mice were challenged intratracheally with 300 mg protein of Ascaris suum extract. In the negative control group, sensitized mice were challenged with saline instead of antigen. Test compound, which was dissolved in a 5% CMC suspension containing 0.03% Tween, was orally administered 1 h before antigen challenge, 8, 24 and 32 h after antigen challenge at a dose of 30 mg/kg (day 22, 23). Forty-eight hours later, the mice were sacrificed by cutting abdominal aorta while the animals were under pentobarbital anesthesia (1.95 mg/0.3 ml i.p. injection). Lungs were lavaged using tracheal polyethylene cannula (outside diameter 1.33 mm, Hibiki No. 4, Hibiki Co.) with 2ϫ0.5 ml Hanks' balanced salt solution supplemented with 0.05 mM potassium EDTA. The BAL fluid was immediately centrifuged (5 min, 4°C, 500ϫ g). After removing the supernatant, the cells in the BAL fluid were resuspended in 0.2 ml of fetal calf serum. The cells were counted in a particle analyzer CDA-500 (Sysmex). Cytocentrifuged preparations (Cytospin 2; Shandon) were stained with Wright's stain solution (Muto Chemicals) for differential counts, based on standard morphologic criteria. Taking the ratio for the number of eosinophils in cytocentrifuged preparations, eosinophils were estimated by multiplication of the ratio and pooled total cells as the mean from each treatment group.
Distribution Coefficient The distribution coefficients (Log D) were determined by the shake-flask method. 30) Milliliters of 400 mM solution of each compound in a 2 ml n-octanol/2 ml PBS solution was placed on a shaker for 30 min. After centrifuging each solution separately at for 10 min, an LC/MS method was used to assay each layer. The LC/MS system was consisted of an 1100 Series LC/MSD (Agilent) and X Terra ® MSC18 3.5 mm, 3.0ϫ30 mm column (Waters). The mobile phase was a 10 mM ammonium acetate buffer (pH 4.5)/0.05% (v/v) acetic acid mixture in acetonitrile; the gradient condition 95/5 to 10/90). Analyst software program (version 1.4, Applied Bio. Systems) was used to calculated the Log D.
Madin-Darby Canine Kidney Cell Permeability The cell permeability of selected compounds was determined using Madin-Darby canine kidney (MDCK, American Type Culture Collection) cells. MDCK cells were maintained in Minimum Essential Medium (GIBCO) containing 10% (v/v) fetal bovine serum (Bioproducts Inc.), a penicillin-streptomycin mixture (GIBCO), and L-glutamine. For the transport assay, cells were seeded on HTS 24 well transwells (Costar) at 3ϫ10 5 cells/ml and grown for 6 d after seeding to allow formation of a cell monolayer. The Transport Buffer was prepared using NaHCO 3 (final 0.35 g/l), D-Glucose (final 3.5 g/l), HEPES (Sigma; final 10 mM), CaCl 2 (final 0.14 g/l) and MgSO 4 (final 0.098 g/l) in ϫ10 Hank's Balanced Salt Solution (GIBCO) and adjusted to pH 6.0 or 7.4 in 1 M HCl or 1 M NaOH. For each test compound a dosing solution containing one of the compounds at a concentration of 10 mM in Transport Buffer (pH 6.0) (100 ml) was added to the apical (A) side of a monolayer. A blank solution containing 4% (w/v) BSA in Transport Buffer (pH 7.4) (600 ml), which was re-adjusted to pH 7.4, was added to the basolateral (B) side of the monolayer. Metoprolol was used as a positive control. After 1 h of incubation at 37°C, aliquots of the apical and basal solutions were separately analyzed on an LC/MS/MS system consisting an Alliance 2790 HPLC (Waters), Atlantis dC18, 2.1 mm I.D.ϫ20 mm L, 3 mm particle size column (Waters), and TSQ7000 mass spectrometer (ThermoQuest). The mobile phase was consisted of a 10 mM HCO 2 NH 4 -acetonitrile step gradient 100/0 to 80/20 to 100/0. The concentration of each compound in the apical and the basolateral solution were determined from a peak area versus concentration standard curve. For each compound, Eq. 1 was used to calculate an apparent permeability coefficient (P app ) from the LC/MS/MS-determined concentration in the basolateral compartment (C b , mM) and the initial 10 mM concentration in the donor compartment. In the following equation 3600 s is the total time for the measurement of compound flux and 0.33 cm 2 is the area of transwell filter. , 18750 units/ml) and heparin (500 units/ml) in 25% (w/v) dextrose. Care was taken to apply only the catheter volume (approx 0.05-0.07 ml) of lock solution in order to minimize systemic exposure to this mixture. Animals were housed in clear PVC boxes with lids in unidirectional air flow rooms maintained controlled temperature (20Ϯ4°C) and relative humidity (50%Ϯ20%) on a 12 h light-dark cycle. Animals were provided food and tap water ad libitum, except for the 12 h fasting (food withdrawn) period prior to test substance administration. For intravenous administration, each compound was dissolved in sterile 0.9% (w/v) saline (pH adjusted to 8.0 with sodium bicarbonate) for a target concentration of 1.0 or 0.75 mg of each compound/ml. Each compound was administered by 2 h intravenous infusion at a targeted dose of 2.4 or 1.5 mg/kg. For oral administration, compound 1 was dissolved in 10% (w/v) aqueous Encapsin ® (hydroxypropyl-bcyclodextrin) for a target concentration of 2 mg/ml and was administered by oral gavage at a targeted dose of 5 mg/kg. Compound 15e was suspended in 0.5% (w/v) aqueous methylcellulose for a target concentration of 0.2 mg/ml and was administered by oral gavage at a targeted dose of 2 mg/kg. Plasma samples were analyzed on an LC/MS/MS method consisting HP 1100 Binary Pump HPLC (Hewlett-Packard), Columbus, C8, 2 mmϫ100 mm, 5 mm column (Phenomenex), and Micro Quattro II mass spectrometer (Micromass, Inc) or 2690 Separations Module (Waters), XDB-C18, 2.1ϫ150 mm, 5 mm column (Zorbax), and TSQ 7000 Triple Stage Quadrupole (Finnigan). The mobile phase was consisted of 2% (v/v) formic acid in water/acetonitrile; the gradient condition 90/10 to 10/90) or 2% (v/v) acetic acid in water/acetonitrile; the gradient condition 76/24 to 55/45). Plasma concentra-
